Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related Cataract

A Phase 2, Randomized, Placebo-Controlled, Double-Masked, Multicenter Safety and Efficacy Study of C-KAD Ophthalmic Solution in Patients With Loss of Visual Acuity Due to Age-Related Cataract

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00793091

Enrollment

Registered

2008-11-19

Start date

2008-11-30

Completion date

2009-09-30

Last updated

2008-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Brief summary

The purpose of this study is to determine the safety and efficacy of C-KAD Ophthalmic Solution in improving visual acuity relative to placebo in patients with age-related cataract

Interventions

DRUGC-KAD Ophthalmic Solution

4 drops applied daily for 120 days

DRUGPlacebo

4 drops applied daily for 120 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

50 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Presence of age-related cataract in the study eye * Best-corrected visual acuity of 20/25 to 20/50 in the study eye

Exclusion criteria

* Any other clinical condition in the eye that may compromise vision * Presence or History of Glaucoma * Presence or history of diabetes * Use of eyedrops * Use of steroids

Design outcomes

Primary

Measure	Time frame
Best-corrected visual acuity by ETDRS	120 Days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026